瓣膜性心脏病合并心房颤动的抗凝治疗 - Suppr

Anticoagulation in Atrial Fibrillation With Valvular Heart Disease.

作者信息

Fonseca Ana Catarina, Jorge Claúdia

机构信息

Department of Neurology Stroke Unit Hospital de Santa Maria Lisbon Portugal.

Institute of Pharmacology and Neurosciences Centro de Estudos Egas Moniz Faculdade de Medicina Universidade de Lisboa Lisbon Portugal.

出版信息

J Am Heart Assoc. 2025 Feb 18;14(4):e038736. doi: 10.1161/JAHA.124.038736. Epub 2025 Feb 14.

DOI:10.1161/JAHA.124.038736

PMID:39950337

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12074761/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e73/12074761/8819dca58a75/JAH3-14-e038736-g001.jpg

相似文献

Anticoagulation in Atrial Fibrillation With Valvular Heart Disease.瓣膜性心脏病合并心房颤动的抗凝治疗

J Am Heart Assoc. 2025 Feb 18;14(4):e038736. doi: 10.1161/JAHA.124.038736. Epub 2025 Feb 14.

Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.心房颤动合并心脏瓣膜异常患者的卒中预防策略：对“瓣膜性”心房颤动的认知：欧洲心律协会调查结果

Europace. 2016 Oct;18(10):1593-1598. doi: 10.1093/europace/euw302.

Use of oral anticoagulants in complex clinical situations with atrial fibrillation.在伴有房颤的复杂临床情况下使用口服抗凝药物。

Med Clin (Barc). 2018 Jun;150 Suppl 1:8-24. doi: 10.1016/S0025-7753(18)30666-3.

"": Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants.“”：直接口服抗凝剂时代的心房颤动和人工瓣膜患者的抗凝管理。

Medicina (Kaunas). 2019 Aug 4;55(8):437. doi: 10.3390/medicina55080437.

Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?直接口服抗凝剂可否用于预防瓣膜性心房颤动患者的卒中？

Curr Cardiol Rep. 2019 Aug 31;21(10):118. doi: 10.1007/s11886-019-1199-4.

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.更新的欧洲心脏节律协会实用指南：非维生素 K 拮抗剂抗凝剂在非瓣膜性心房颤动患者中的应用：执行摘要。

Eur Heart J. 2017 Jul 14;38(27):2137-2149. doi: 10.1093/eurheartj/ehw058.

Prevalence and Prognostic Implications of Valve Disease in Patients With Atrial Fibrillation Initiating Direct Oral Anticoagulants.启动直接口服抗凝剂的心房颤动患者瓣膜病的患病率及其预后意义

Rev Esp Cardiol (Engl Ed). 2019 Nov;72(11):935-943. doi: 10.1016/j.rec.2018.08.026. Epub 2018 Nov 27.

Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).心房颤动合并心脏瓣膜病的抗栓治疗：欧洲心律协会（EHRA）和欧洲心脏病学会血栓工作组的联合共识文件，得到 ESC 心脏瓣膜病工作组、南非心脏协会（SA Heart）、心律学会（HRS）、亚太心律学会（APHRS）、南非心脏协会（SA Heart）和拉丁美洲心脏刺激和电生理学会（SOLEACE）的认可。

Europace. 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240.

Long-term oral anticoagulation for atrial fibrillation in low and middle income countries.中低收入国家的心房颤动长期口服抗凝治疗。

Indian Heart J. 2021 Mar-Apr;73(2):244-248. doi: 10.1016/j.ihj.2021.02.003. Epub 2021 Feb 10.

Anticoagulation and atrial fibrillation.抗凝与心房颤动

Herz. 1993 Feb;18(1):27-38.

引用本文的文献

Critique on "Evaluation of the Presence of Native Valvular Disease in Patients With Atrial Fibrillation Using the EHRA (Evaluated Heartvalves, Rheumatic, or Artificial) Classification".对“使用EHRA（评估心脏瓣膜、风湿性或人工瓣膜）分类法评估心房颤动患者原生瓣膜疾病的存在情况”的评论

Clin Cardiol. 2025 Sep;48(9):e70207. doi: 10.1002/clc.70207.

本文引用的文献

Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Without Mechanical Valves.非机械瓣膜的心房颤动和瓣膜性心脏病患者中直接口服抗凝剂与华法林的比较

J Am Heart Assoc. 2025 Feb 18;14(4):e035478. doi: 10.1161/JAHA.124.035478. Epub 2025 Feb 14.

2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).2024年欧洲心脏病学会（ESC）心房颤动管理指南，与欧洲心胸外科学会（EACTS）联合制定。

Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared with Vitamin K Antagonists in Patients with Atrial Fibrillation and Type 2 Valvular Heart Disease: A Systematic Review and Meta-Analysis.非维生素K拮抗剂口服抗凝药与维生素K拮抗剂在心房颤动合并2型瓣膜性心脏病患者中的疗效和安全性：一项系统评价和荟萃分析

Cardiovasc Drugs Ther. 2024 Aug 17. doi: 10.1007/s10557-024-07616-7.

Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve.阿哌沙班或华法林用于 On-X 机械主动脉瓣患者。

NEJM Evid. 2023 Jul;2(7):EVIDoa2300067. doi: 10.1056/EVIDoa2300067. Epub 2023 May 6.

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南：心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。

J Am Coll Cardiol. 2024 Jan 2;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017. Epub 2023 Nov 30.

Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.利伐沙班在风湿性心脏病相关心房颤动中的应用。

N Engl J Med. 2022 Sep 15;387(11):978-988. doi: 10.1056/NEJMoa2209051. Epub 2022 Aug 28.

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.直接口服抗凝药与华法林在心房颤动患者中的比较：按年龄和性别进行交互测试的随机临床试验的患者水平网络荟萃分析。

Circulation. 2022 Jan 25;145(4):242-255. doi: 10.1161/CIRCULATIONAHA.121.056355. Epub 2022 Jan 5.

Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.直接口服抗凝剂与华法林治疗瓣膜性心房颤动患者的有效性和安全性：基于人群的队列研究。

Ann Intern Med. 2021 Jul;174(7):910-919. doi: 10.7326/M20-6194. Epub 2021 Mar 30.

Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension-a Systematic Review.直接口服抗凝剂的超适应证应用：瓣膜性心房颤动、心力衰竭、左心室血栓、浅静脉血栓形成、肺动脉高压——系统评价。

Ann Pharmacother. 2021 Aug;55(8):995-1009. doi: 10.1177/1060028020970618. Epub 2020 Nov 4.

Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study.达比加群酯用于中重度二尖瓣狭窄患者房颤卒中预防的方案、原理及设计（DAVID-MS）：一项随机、开放标签研究

BMJ Open. 2020 Sep 25;10(9):e038194. doi: 10.1136/bmjopen-2020-038194.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulation in Atrial Fibrillation With Valvular Heart Disease.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献